Skip to main content
TipRanks
Go Ultimate75% OFF

Argenica Therapeutics Ltd (AGN) Stock Statistics & Valuation Metrics

14 Followers

Total Valuation

Argenica Therapeutics Ltd has a market cap or net worth of AUD 15.41M. The enterprise value is AUD 32.86M.

Market Cap
AUD 15.41M
Enterprise Value
AUD 32.86M

Share Statistics

Argenica Therapeutics Ltd has 128,456,710 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding
128,456,710
Owned by Insiders
0.11%
Owned by Institutions
―

Financial Efficiency

Argenica Therapeutics Ltd’s return on equity (ROE) is -0.23 and return on invested capital (ROIC) is -30.59%.

Return on Equity (ROE)
-0.23
Return on Assets (ROA)
-0.21
Return on Invested Capital (ROIC)
-30.59%
Return on Capital Employed (ROCE)
-1.20
Revenue Per Employee
0
Profits Per Employee
-195.05K
Employee Count
7
Asset Turnover
0.00
Inventory Turnover
0.00

Valuation Ratios

The current PE Ratio of Argenica Therapeutics Ltd is -11.32. Argenica Therapeutics Ltd’s PEG ratio is -0.62.

PE Ratio
-11.32
PS Ratio
0.00
PB Ratio
2.61
Price to FCF
-3.68
Price to Operating Cash Flow
-3.68
PEG Ratio
-0.62

Income Statement

In the last 12 months, Argenica Therapeutics Ltd had revenue of 0 and earned -1.37M in profits. Earnings per share was -0.01.

Revenue
0
Gross Profit
0
Operating Income
-7.06M
Pretax Income
-5.34M
Net Income
-1.37M
EBITDA
-7.06M
Earnings Per Share (EPS)
-0.01

Cash Flow

In the last 12 months, operating cash flow was -4.19M and capital expenditures 0, giving a free cash flow of -4.19M billion.

Operating Cash Flow
-4.19M
Free Cash Flow
-4.19M
Free Cash Flow per Share
-0.03

Dividends & Yields

Argenica Therapeutics Ltd pays an annual dividend of ―, resulting in a dividend yield of ―

Dividend Per Share
―
Dividend Yield
―
Payout Ratio
N/A
Free Cash Flow Yield
-27.18%
Earnings Yield
-8.86%

Stock Price Statistics

Beta
1.48
52-Week Price Change
-52.00%
50-Day Moving Average
0.13
200-Day Moving Average
0.16
Relative Strength Index (RSI)
50.07
Average Volume (3m)
77.67K

Important Dates

Argenica Therapeutics Ltd upcoming earnings date is Mar 02, 2027, TBA (Not Confirmed).

Last Earnings Date
Feb 10, 2026
Next Earnings Date
Mar 02, 2027
Ex-Dividend Date
―

Financial Position

Argenica Therapeutics Ltd as a current ratio of 10.60, with Debt / Equity ratio of 0.00%

Current Ratio
10.60
Quick Ratio
10.60
Debt to Market Cap
0.00
Net Debt to EBITDA
0.90
Interest Coverage Ratio
0.00

Taxes

In the past 12 months, Argenica Therapeutics Ltd has paid -3.97M in taxes.

Income Tax
-3.97M
Effective Tax Rate
0.74

Enterprise Valuation

Argenica Therapeutics Ltd EV to EBITDA ratio is -1.28, with an EV/FCF ratio of -2.16.

EV to Sales
0.00
EV to EBITDA
-1.28
EV to Free Cash Flow
-2.16
EV to Operating Cash Flow
-2.16

Balance Sheet

Argenica Therapeutics Ltd has AUD 6.36M in cash and marketable securities with AUD 0.00 in debt, giving a net cash position of AUD 6.36M billion.

Cash & Marketable Securities
AUD 6.36M
Total Debt
AUD 0.00
Net Cash
AUD 6.36M
Net Cash Per Share
AUD 0.05
Tangible Book Value Per Share
AUD 0.05

Margins

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

Gross Margin
0.00%
Operating Margin
0.00%
Pretax Margin
0.00%
Net Profit Margin
0.00%
EBITDA Margin
0.00%
EBIT Margin
0.00%

Analyst Forecast

The average price target for Argenica Therapeutics Ltd is ―, which is 11.43% higher than the current price. The consensus rating is ―

Price Target
―
Price Target Upside
―
Analyst Consensus
―
Analyst Count
―
Revenue Growth Forecast
―
EPS Growth Forecast
81.00%

Scores

Smart Score
6
AI Score
45